An investigation of the effects of intranasal oxytocin on socio-emotional brain regions in Huntington’s disease

• Conditions: Huntington's disease; Neurological - Neurodegenerative diseases; Mental Health - Other mental health disorders; Human Genetics and Inherited Disorders - Other human genetics and inherited disorders

• Registration Number: ACTRN12613000026729
• Lead Sponsor: Monash Biomedical Imaging

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-01-09
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: Male
• Target Recruitment: 40

Inclusion Criteria

For Healthy controls: Males; Right-handed; between the ages of 25-55 years; non-smoker and no drug/alcohol abuse; medication free; and no metal objects present in body (or which can't be removed or which is not MRI safe).
For Huntington's disease (HD): As above plus a diagnosis of the disease is required.

Exclusion Criteria

Clinically significant medical or neurological condition (other than HD for the patients), significant head injury (or loss of consciousness from longer than 5 mins), presence of ferrous-containing metals within the body, inability to tolerate small enclosed spaces without anxiety.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Functional MRI (fMRI) data will be collected in response to an emotional face expression task. The fMRI data will be compared within the patient (Huntington's disease) group for differences in brain response (e.g., in the amygdala) between placebo and oxytocin conditions. [The data will be collected in the 50-80 min post drug administration and will be analysed post all data collection.]

Secondary Outcome Measures

Name	Time	Method
sing the fMRI data, the patients with Huntington's disease will be compared to controls on brain response (e.g., amygdala) under normal (placebo) conditions to see whether hyper- or hypo-activity is present.[The data will be collected in the 50-80 min post drug administration and will be analysed post all data collection.]